- Albireo Pharma (NASDAQ:ALBO) initiated with Outperform rating by Cowen and Company.
- ObsEva (NASDAQ:OBSV) initiated with Outperform rating and $18 (134% upside) price target by Leerink.
- Dextera Surgical (OTC:DXTR) initiated with Buy rating and $0.80 (220% upside) price target by Ladenburg Thalmann.
- Spectrum Pharmaceuticals (NASDAQ:SPPI) resumed with Buy rating and $14 (49% upside) price target by H.C. Wainwright citing upside with Rolontis and poziotinib.
- Biogen (NASDAQ:BIIB) added to Conviction Buy List at Goldman Sachs.
- Mylan N.V. (NASDAQ:MYL) upgraded to Buy by Citigroup. Shares up 3% premarket.
- Prometic Life Sciences (OTCQX:PFSCF) downgraded to Sector Perform by National Bank.
- Teva Pharmaceutical Industries (NYSE:TEVA) downgraded to Neutral by Citigroup.
- Aevi Genomic Medicine (NASDAQ:GNMX) price target lowered to $7 (407% upside) from $9 by Needham citing dilution from recent financing.